Tongjitang to Enhance Product Portfolio with a Leading Pulmonary Disease Treatment in China

March 20, 2008 -Tongjitang Chinese Medicines Company (NYSE: TCM) , a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it has signed a definitive purchase agreement to acquire Qinghai Pulante Pharmaceutical Co. Ltd. ("Pulante"), a privately owned plant-based pharmaceutical company...
...Pulante is located in Xining in the Qinghai province of China and was founded in 2000. It develops, manufactures, markets, and distributes SFDA-approved Tibetan recipe-originated medicines in China. Pulante’s major revenue-generating product, Chongcao Qingfei Capsules, is an OTC product which alleviates the symptoms of respiratory diseases, and targets patients with Chronic Obstructive Pulmonary Disease ("COPD"), a common disease among more than 300 million smokers in China. In 2007, Pulante generated revenue of approximately RMB40 million and was profitable. Pulante’s manufacturing facility in Xining is a GMP-certified manufacturing facility. ... Tongjitang's Press Release -